Spyre Therapeutics Inc (SYRE) Stock Analysis
Verdict: WATCH (do not buy)
A $7.7B valuation for preclinical IBD assets leaves zero margin for error if early human trials fail to beat incumbent biologics.
Investment score: 44/100
Analysis as of
Is Spyre Therapeutics Inc stock worth reviewing? The TradeMates thesis
A $7.7B valuation for preclinical IBD assets leaves zero margin for error if early human trials fail to beat incumbent biologics.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 50/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Spyre Therapeutics Inc opportunities and risks
What speaks for SYRE
- Differentiated anti-TL1A and anti-a4ß7 portfolio targeting massive IBD market
What speaks against SYRE
- Binary clinical trial failure across preclinical candidates SPY001 and SPY002
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SYRE | n/a | 83.8x | n/a | 0.0% | -197.7% | -2.8% |
| TGTX | 18.3x | 10.7x | 65.5x | 82.4% | 55.2% | -0.0% |
| TWST | n/a | 17.9x | n/a | 52.0% | -31.7% | -1.2% |
| IMVT | n/a | 1134.8x | n/a | 97.1% | -7585.9% | -5.1% |
| RYTM | n/a | 29.5x | n/a | 89.0% | -85.6% | -2.1% |
| CAI | 67.0x | 7.1x | 39.4x | 69.7% | 10.6% | 2.1% |
| Peer median | n/a | 17.9x | n/a | 82.4% | -31.7% | -1.2% |
Frequently asked questions about Spyre Therapeutics Inc (SYRE)
Is SYRE stock a good investment?
The TradeMates model rates Spyre Therapeutics Inc as WATCH (do not buy) with an investment score of 44/100. A $7.7B valuation for preclinical IBD assets leaves zero margin for error if early human trials fail to beat incumbent biologics. This is algorithmic model output, not personal investment advice.
Is SYRE stock a buy?
The TradeMates model verdict for SYRE is WATCH (do not buy) with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.